it would seem that way, everything i can find has BTX1801 headed for "phase 1b/2". some other articles suggest it had leverage from the 1803 results. phase 1 being largely for safety and dosage, perhaps the these were confirmed by 1803 MOA, positioning BOT to trial the 'antimicrobial' application at ph2 directly.
Ann: Botanix Initiates BTX 1702 Rosacea Study, page-16
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.005(1.52%) |
Mkt cap ! $527.6M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 34.5¢ | 33.0¢ | $1.680M | 4.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 1122715 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 22219 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |